Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Ansquer

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
European Journal of Nuclear Medicine and Molecular Imaging|December 6, 2023
Performance of [<sup>18</sup>F]fluorocholine PET/CT in MEN1-related primary hyperparathyroidism before initial surgery or for persistent/recurrent diseaseAymeric Boucher, Julia Delabie, Charlotte Lussey-Lepoutre, et al.
The Journal of Clinical Endocrinology and Metabolism|December 23, 2021
Value of Somatostatin Receptor PET/CT in Patients With MEN1 at Various Stages of Their DiseaseClément Mennetrey, Maëlle Le Bras, Aurélie Bando-Delaunay, et al.
European Journal of Endocrinology|December 6, 2019
Impact of total thyroidectomy on quality of life at 6 months: the prospective ThyrQoL multicentre trialE Mirallié, F Borel, C Tresallet, et al.
The Lancet. Oncology|June 1, 2026
[<sup>177</sup>Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trialEric Baudin, Alice Durand, Amandine Beron, et al.
Lancet (London, England)|July 2, 2026
[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trialThomas Walter, Henning Jann, Catherine Ansquer, et al.
BMC Cancer|April 4, 2025
A Randomized clinical trial evaluating the impact on survival and quality of life of <sup>177</sup>Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)Jaume Capdevila, Virginia Pubul, Urbano Anido, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 4, 2020
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with <sup>177</sup>Lu-Dotatate: an analysis of the NETTER-1 studyJonathan Strosberg, Pamela L Kunz, Andrew Hendifar, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
European Journal of Nuclear Medicine and Molecular Imaging|December 6, 2023
Performance of [<sup>18</sup>F]fluorocholine PET/CT in MEN1-related primary hyperparathyroidism before initial surgery or for persistent/recurrent diseaseAymeric Boucher, Julia Delabie, Charlotte Lussey-Lepoutre, et al.
The Journal of Clinical Endocrinology and Metabolism|December 23, 2021
Value of Somatostatin Receptor PET/CT in Patients With MEN1 at Various Stages of Their DiseaseClément Mennetrey, Maëlle Le Bras, Aurélie Bando-Delaunay, et al.
European Journal of Endocrinology|December 6, 2019
Impact of total thyroidectomy on quality of life at 6 months: the prospective ThyrQoL multicentre trialE Mirallié, F Borel, C Tresallet, et al.
The Lancet. Oncology|June 1, 2026
[<sup>177</sup>Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trialEric Baudin, Alice Durand, Amandine Beron, et al.
Lancet (London, England)|July 2, 2026
[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trialThomas Walter, Henning Jann, Catherine Ansquer, et al.
BMC Cancer|April 4, 2025
A Randomized clinical trial evaluating the impact on survival and quality of life of <sup>177</sup>Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)Jaume Capdevila, Virginia Pubul, Urbano Anido, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 4, 2020
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with <sup>177</sup>Lu-Dotatate: an analysis of the NETTER-1 studyJonathan Strosberg, Pamela L Kunz, Andrew Hendifar, et al.
Pageof 5